Barclays initiated coverage of West Pharmaceutical Services with an equalweight rating on June 24, 2025.
1 report, 0 independent
Updated Jun 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Barclays initiated coverage of West Pharmaceutical Services with an equalweight rating on June 24, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Barclays
British bank
- QinetiQ carried out share purchases and arranged for a share buyback execution on the London Stock Exchange.
- Financial institutions provided ratings on multiple companies on July 8, 2026, including Goldman Sachs reiterating Tesla as neutral, Barclays initiating Toast as overweight, and Bank of America rating Nvidia as a buy.
-
West Pharmaceutical Services (United States)
American healthcare company
Nothing else this week.
Related events
- Barclays maintained Overweight rating and raised price target on August 29, 2025.
- Morgan Stanley reaffirmed an overweight rating on AbbVie, and Barclays raised its price objective on September 10, 2026.
- Barclays reiterated an overweight rating on the stock of Brighthouse Financial.
- Barclays issued rating and price objective reports for Ubiquiti on August 1, 2026.
Coverage
Newest first; wire copies grouped- Unknown outlet